8 results about "Alpha-toxin" patented technology

The invention belongs to the technical field of bioengineering, and discloses a monoclonal antibody specifically combined with clostridium septicum alpha toxin recombinant protein, a hybridoma cell strain and application. The invention provides a monoclonal antibody which is specifically combined with clostridium septicum alpha toxin protein and a hybridoma cell strain clostridium septicum alpha toxin-8H2 which secretes the monoclonal antibody and has the preservation number of CCTCC NO: C202535, the monoclonal antibody only reacts with the clostridium septicum alpha toxin protein, and does not have cross reaction with other pathogens which infect cattle and sheep; the specificity is extremely high; according to the kit, a competitive ELISA technology is utilized, a mouse monoclonal antibody specifically combined with clostridium septicum alpha toxin recombinant protein is taken as a competitive antibody, serum antibodies of various animal sources can be detected, and species limitation of sample sources is avoided. Besides, the kit is good in repeatability, relatively loose in technical requirements during operation, capable of being widely popularized and used in production, and applied to clostridium septicum epidemiological investigation and vaccine immune level monitoring.

The invention relates to clostridium perfringens in excrement as a molecular marker for grading and judging fatty liver diseases related to metabolic dysfunction and application of the clostridium perfringens, the clostridium perfringens contains alpha toxin CPA according to the types of main toxins generated by the clostridium perfringens, the coding gene of the alpha toxin CPA is plc gene, and the content of the alpha toxin CPA is determined by quantitatively detecting the plc gene. The molecular level detection of the clostridium perfringens in the excrement sample is realized; besides, the clostridium perfringens further contain nirA genes related to nitrogen metabolism, the nirA genes participate in the metabolic process related to microbial ammonia production, the functional state of the intestinal ammonia-producing microorganisms is reflected by detecting the expression level of the nirA genes, stable acquisition of the molecular characteristics of the intestinal microorganisms related to the MASLD is achieved, and the application prospect is broad. A molecular basis is provided for analyzing the correlation between the abnormal ammonia metabolism and the occurrence and development of the MASLD.

The present invention provides molecules of recombinant nucleic acid that encode epitopes of alpha toxin of recombinant C. novyi. Additionally, the invention provides vaccine compositions comprising said epitopes and use of same, and a method for preparing said compositions. Finally, the invention also provides a method for treating and preventing clostridiosis.

The invention provides a clostridium septicum alpha toxin mutant as well as a preparation method and application thereof, and relates to the technical field of biology, leucine at the 403rd site of an amino acid sequence as shown in SEQ ID NO.1 is mutated into amino acid X, the amino acid X is any one of isoleucine, valine or methionine, and the amino acid X is any one of isoleucine, valine or methionine. Compared with the existing recombinant clostridium septicum alpha toxin, the clostridium septicum alpha toxin mutant has the advantages that the protein expression quantity is further improved, the storage life is longer, and the stability is better.

This invention belongs to the field of pathogen and toxin detection technology, specifically relating to a polyclonal antibody colloidal gold test strip for detecting Clostridium perfringens α toxin and its application. The polyclonal antibody colloidal gold test strip includes a PVC base plate, on which a sample pad, a gold-labeled pad, a chromatography membrane, and an absorbent pad are sequentially overlapped. The gold-labeled pad is coated with colloidal gold particles labeled with polyclonal antibodies against Clostridium perfringens α toxin. A detection line and a control line are sequentially arranged on the chromatography membrane. The detection line is coated with polyclonal antibodies against Clostridium perfringens α toxin, and the control line is coated with goat anti-rabbit IgG (H+L) antibody. The amino acid sequence of the recombinant protein of Clostridium perfringens α toxin is shown in SEQ ID NO.3. The polyclonal antibody colloidal gold test strip provided by this invention can be used for the detection of Clostridium perfringens α toxin, with a detection limit of 31.25 μg / mL.

The invention belongs to the field of biology, and discloses swine A type clostridium perfringens SP20 capable of secreting and expressing high-level alpha toxin, which is preserved in the China Center for Type Culture Collection (CCTCC) with the preservation number of CCTCC NO: M 2025386. The strain has strong pathogenicity to medium and large pigs, and can be used for establishment of a pig challenge model and efficacy evaluation of a pig A-type clostridium perfringens vaccine. The invention further discloses a vaccine for preventing intestinal flatulence and sudden death of medium and large pigs caused by the A-type clostridium perfringens. The vaccine comprises the alpha toxin generated by the SP20 strain. The invention fills the blank of the disease model of intestinal flatulence and sudden death of middle and large pigs, and is beneficial to control of disease infection and reduction of economic loss of breeding industry.

The invention relates to the technical field of clostridium septicum antigens, in particular to a clostridium septicum alpha toxin mutant as well as a preparation method and application thereof. The nucleotide sequence of the clostridium septicum alpha toxin mutant is as shown in SEQ ID NO: 1. The clostridium septicum alpha toxin mutant provided by the invention can effectively stimulate humoral immunity and cellular immunity of an organism, and a new thought is provided for development of a clostridium septicum subunit vaccine.

The present disclosure is directed to methods of treating subjects colonized with S. aureus with an anti-alpha toxin antibody or antigen-binding fragment thereof. The methods can decrease the incidence of infection attendant to the presence of S. aureus in the subject.